Study on Mirvetuximab treatment cycle for ovarian cancer

Mirvetuximab (Mirvetuximab), as a new type of antibody drug conjugate (ADC), is mainly used to treat patients with relapsed or refractory ovarian cancer with high FRα expression. The treatment cycle is designed based on drug pharmacokinetics, tumor cytotoxicity and clinical tolerance, and is usually administered once every 3 weeks (21-day cycle). In clinical studies, this cycle design not only ensures the effective concentration of the drug in the blood and tissues, but also takes into account patient tolerance and safety. Studies have shown that regular medication for multiple cycles can achieve sustained effects in tumor control and symptom relief, while reducing the occurrence of serious side effects.

Somituximabby specifically bindingFRα receptor, delivers cytotoxic drugs directly into cancer cells, accurately killing tumor tissues. During the treatment process, during each 21-day cycle, the drug reaches its peak concentration in the body and is gradually eliminated by metabolism, providing a time window for the next dose. This interval not only helps reduce hematological toxicity and liver function damage, but also helps patients restore their overall health and improve their quality of life. Clinical studies have also shown that continuous treatment for multiple cycles can maintain tumor control, and some patients show tumor shrinkage or a decrease in serum tumor markers after multiple cycles.

Patients typically receive adequate conditioning prior to treatment cycles, including corticosteroids, antihistamines, and antipyretics to reduce the risk of drug infusion-related reactions. In addition, to prevent adverse eye reactions, doctors will recommend the use of eye steroid ointments, lubricating eye drops and antiemetic drugs. Clinical studies have emphasized that regular and continuous treatment cycles are the key to ensuring the efficacy of somituximab, and regular monitoring of hematological indicators and liver and kidney function during the cycle are important measures to maintain treatment safety.

Reference materials:https://www.elahere.com/